Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosigotifator Safety and PK Study in ALS
NCT04948645Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- Sep 2021
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of fosigotifator in amyotrophic lateral sclerosis (ALS) (4 arms), sponsored by AbbVie Inc. Primary endpoints: Safety and Tolerability at Day 28 and Pharmacokinetics at Day 28. Started Sep 2021; status: terminated.
02
Drugs
fosigotifator
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04948645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04948645.